ME-344
| Drug Information | |||
|---|---|---|---|
| Image | |||
| Identifiers
CAS Number ATC Code PubChem DrugBank ChemSpider ID UNII KEGG ChEBI ChEMBL IUPAC Name |
Chemical Data
C H N O Molecular Weight | ||
ME-344 is an investigational drug that is being studied for its potential use in the treatment of various types of cancer. It is a second-generation isoflavone-derived compound that has shown promise in preclinical and early clinical trials due to its ability to inhibit mitochondrial function in cancer cells.
Mechanism of Action[edit | edit source]
ME-344 works by targeting the mitochondria of cancer cells. Mitochondria are the powerhouses of the cell, responsible for producing energy in the form of adenosine triphosphate (ATP). ME-344 disrupts the mitochondrial function, leading to a decrease in ATP production, which in turn induces cell death in cancer cells. This mechanism is particularly effective in cancer cells due to their high energy demands and reliance on mitochondrial function for survival and proliferation.
Clinical Trials[edit | edit source]
ME-344 has been evaluated in several clinical trials to assess its safety and efficacy. Early-phase trials have focused on its use in combination with other chemotherapeutic agents to enhance its anticancer effects. Results from these studies have shown that ME-344 can be safely administered and may enhance the efficacy of existing cancer treatments.
Phase I Trials[edit | edit source]
The initial phase I trials of ME-344 were designed to determine the maximum tolerated dose and to evaluate its safety profile. These studies involved patients with advanced solid tumors who had exhausted standard treatment options. The trials demonstrated that ME-344 was well-tolerated at certain dose levels and provided preliminary evidence of antitumor activity.
Phase II Trials[edit | edit source]
Subsequent phase II trials have explored the use of ME-344 in specific cancer types, such as breast cancer and ovarian cancer. These studies aim to further evaluate the drug's efficacy and to identify potential biomarkers that could predict response to treatment.
Potential Applications[edit | edit source]
Given its mechanism of action, ME-344 has potential applications in a variety of cancers, particularly those that are resistant to conventional therapies. Its ability to target the mitochondria makes it a promising candidate for combination therapy, where it can be used alongside other drugs to enhance their effectiveness.
Side Effects[edit | edit source]
As with many investigational drugs, ME-344 has been associated with certain side effects. Commonly reported adverse effects include fatigue, nausea, and changes in liver function tests. Ongoing studies continue to monitor the safety profile of ME-344 to better understand its long-term effects.
Also see[edit | edit source]
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
